Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | SELL | P14151 | 2/20 | 0.49 |
| ▸ | SELP | P16109 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | CASR | P41180 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SELE | P16581 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30816854 | 0.90 | MAPT (0.43) | PPARGL3MBTL1GAAMAPK1MAPT | |
| SCHEMBL9104625 | 0.88 | CA12 (0.44) | MAPK1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL30587156 | 0.88 | MAPT (0.46) | L3MBTL1MAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL628865 | 0.88 | MAPT (0.46) | L3MBTL1MAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL3256083 | 0.88 | NPC1 (0.54) | MAPK1MAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL10318265 | 0.87 | ALDH1A1 (0.50) | L3MBTL1GAAMAPTALDH1A1KDM4E | |
| SCHEMBL1417067 | 0.85 | PPARG (0.46) | PPARGL3MBTL1GAAMAPK1MAPT | |
| SCHEMBL11982645 | 0.85 | HDAC1 (0.46) | HDAC1HDAC8HDAC6 | |
| SCHEMBL30779358 | 0.85 | MAPT (0.46) | GAAMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL9865843 | 0.85 | KDM5A (0.50) | L3MBTL1GAAMAPK1MAPTSELL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| US-8563558-B2 | Substituted pyridine urea compounds | CONFLUENCE LIFE SCIENCES, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130172352-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8410160-B2 | 5-membered heterocycle-based P38 kinase inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8394968-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-12 | — | — | US | disclosed |
| US-8242117-B2 | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| WO-2012098070-A1 | QUINOLINE DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098070-A1 | QUINOLINE DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184548-A1 | CARBOXYLIC ACID ARYL AMIDES | DOMINIQUE ROMYR (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184548-A1 | CARBOXYLIC ACID ARYL AMIDES | DOMINIQUE ROMYR (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2011021678-A1 | FUSED HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2011-02-24 | — | — | WO | disclosed |
| US-7863314-B2 | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2011-01-04 | — | — | US | disclosed |
| EP-1409463-B1 | N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION | BRISTOL MYERS SQUIBB CO (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-1242385-B1 | CYTOKINE, ESPECIALLY TNF-ALPHA, INHIBITORS | PHARMACOPEIA INC (US) | 2009-11-25 | — | — | EP | disclosed |
| US-7479495-B2 | N-heterocyclic inhibitors of TNF-α expression | PHARMACOPEIA, INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-7211666-B2 | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-01 | — | — | US | disclosed |
| US-7148243-B2 | Antivirals | MEDIVIR AB (SE) | 2006-12-12 | — | — | US | disclosed |
| EP-1054867-B1 | ANTIVIRALS | MEDIVIR AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| US-20030119881-A1 | N-((2-hydroxy,3-(alkyloxo),6-halophenyl)-(1,2-cyclopropylene) -),N'-((5-cyano or bromo)pyrid-2-yl)urea; retroviricides; HIV reverse transcriptase inhibitors; prolonged time to virus resistance | MEDIVIR AB (SE) | 2003-06-26 | — | — | US | disclosed |
| US-6486183-B1 | Antivirals | MEDIVIR AB (SE) | 2002-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119881-A1 | N-((2-hydroxy,3-(alkyloxo),6-halophenyl)-(1,2-cyclopropylene) -),N'-((5-cyano or bromo)pyrid-2-yl)urea; retroviricides; HIV reverse transcriptase inhibitors; prolonged time to virus resistance | RAD1, POLL, PNPO | PPARG 4182/4885L3MBTL1 1487/4885GAA 2711/4885 |
| US-20130172352-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | PPARG 437/4885L3MBTL1 2317/4885GAA 2748/4885 |
| US-20120184548-A1 | CARBOXYLIC ACID ARYL AMIDES | GOT1, PPARG, PPARA | PPARG 2/4885L3MBTL1 4430/4885GAA 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.